Compare · NVO vs PVLA
NVO vs PVLA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Palvella Therapeutics Inc. (PVLA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and PVLA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 98.8x PVLA ($2.26B).
- PVLA has been more active in the news (9 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 15 for PVLA).
- Company
- Novo Nordisk A/S
- Palvella Therapeutics Inc.
- Price
- -
- -
- Market cap
- $222.81B
- $2.26B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 9
- Recent ratings
- 25
- 15
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest PVLA
- Chief Operating Officer Goin Kathleen exercised 4,302 shares at a strike of $8.11 and sold $642,191 worth of shares (4,302 units at $149.28) as part of a pre-agreed trading plan (SEC Form 4)
- Palvella Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 4 filed by Director Pauls Matthew
- SEC Form 3 filed by new insider Pauls Matthew
- Palvella Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
- Chief Operating Officer Goin Kathleen sold $476,373 worth of shares (4,302 units at $110.73) as part of a pre-agreed trading plan and exercised 4,302 shares at a strike of $8.11 (SEC Form 4)
- FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
- CFO, Treasurer Korenberg Matthew E exercised 1,000 shares at a strike of $13.60 (SEC Form 4)